Up Close with Linvoseltamab
Last Updated: May 16, 2025
This section provides an overview of linvoseltamab-gcpt (LYNOZYFIC™).
Find Similar Resources:
Immunotherapy
Immunotherapy
Immunotherapy
Immunotherapy
Example SOPs and Documents: Transitioning Patients on Bispecific T-Cell Engagers Between Care Settings
Last Updated: 09/14/2025
Example SOPs and Documents: Bispecific T-cell Engager Billing Procedure
Last Updated: 09/14/2025
Example SOPs and Documents: Bispecific T-Cell Engager Ordering and REMS Compliance
Last Updated: 09/14/2025
Example SOPs and Documents: On-Call Responsibilities for Nurses Managing Bispecific T-Cell Engagers
Last Updated: 09/14/2025
PQI Podcast
PQI in Action
PQI in Action
PQI Podcast
S9 E3: Firefighter Health & Cancer Prevention
Author: Ginger Blackmon, PharmD | Tim Thompson
Last Updated: 09/14/2025
PQI in Action: Abiraterone acetate (Yonsa®) Patient Selection and Management
Author: Atlanticare Cancer Care Institute | Cancer Specialists of North Florida
Last Updated: 09/14/2025
PQI in Action: Enfortumab Vedotin-ejfv (Padcev®) and Pembrolizumab (Keytruda®) Management for Advanced or Metastatic Urothelial Carcinoma
Author: Huntsman Cancer Institute | University Hospitals
Last Updated: 09/14/2025
S9 E2: Love Languages in Cancer Care
Author: Ginger Blackmon, PharmD | Jenny Hoang, PharmD
Last Updated: 09/14/2025